Pharsight

Lenvima patents expiration

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(1 year, 7 months from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(2 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(3 years from now)

US11090386 EISAI INC Method for suppressing bitterness of quinoline derivative
Feb, 2036

(12 years from now)

Lenvima is owned by Eisai Inc.

Lenvima contains Lenvatinib Mesylate.

Lenvima has a total of 7 drug patents out of which 0 drug patents have expired.

Lenvima was authorised for market use on 13 February, 2015.

Lenvima is available in capsule;oral dosage forms.

Lenvima can be used as treatment with lenvima by administering lenvima as a suspension, method for treating thyroid carcinoma including differentiated thyroid cancer.

The generics of Lenvima are possible to be released after 23 February, 2036.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
M (M) Dec 19, 2024
New Indication (I) Aug 10, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents